Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naïve Patients With Chronic Genotype 2 or 3 HCV Infection
Brief Summary: This study was to assess the safety and efficacy of sofosbuvir (GS-7977; PSI-7977) in combination with ribavirin (RBV) administered for 12 weeks compared with pegylated interferon (PEG)/RBV administered for 24 weeks in treatment-naive patients with Hepatitis C (HCV) genotype 2 or 3. Efficacy was assessed by the rate of sustained viral response (SVR) 12 weeks after the discontinuation of therapy (SVR12). This was a non-inferiority study, and if non-inferiority was demonstrated, the study was then allowed to test for superiority.


Options:
A: Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin | Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Placebo for ribavirin | Intervention Type: DRUG; Name: ABT-450/r/ABT-267, ABT-333; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV, ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Placebo for ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV
B: Arm Label: Sofosbuvir+RBV; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV | Arm Label: PEG+RBV; Type: ACTIVE_COMPARATOR; Interventions: Drug: PEG, Drug: RBV | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Sofosbuvir+RBV | Intervention Type: DRUG; Name: PEG; Assigned to Arm(s): PEG+RBV | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): PEG+RBV, Sofosbuvir+RBV
C: Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin | Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Placebo for Ribavirin | Intervention Type: DRUG; Name: ABT-450/r/ABT-267, ABT-333; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV, ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Placebo for Ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV
D: Arm Label: Placebo + Peg-IFN/Ribavirin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin | Arm Label: Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Vaniprevir, Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin | Arm Label: Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Vaniprevir, Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin | Arm Label: Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Vaniprevir, Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin | Arm Label: Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Vaniprevir, Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin, Drug: Comparator: placebo | Intervention Type: DRUG; Name: Comparator: Vaniprevir; Assigned to Arm(s): Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin, Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin | Intervention Type: DRUG; Name: Comparator: Pegylated-Interferon (Peg-IFN); Assigned to Arm(s): Placebo + Peg-IFN/Ribavirin, Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin, Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin | Intervention Type: DRUG; Name: Comparator: Ribavirin; Assigned to Arm(s): Placebo + Peg-IFN/Ribavirin, Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin, Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin | Intervention Type: DRUG; Name: Comparator: placebo; Assigned to Arm(s): Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin

Answer: B